Skip to main content
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

Med Tech-related technology assessments and clinical guidelines from NICE in November 2022

Interventional Procedures Guidance (IPG) is developed for most of the novel interventional procedures entering the English market. The program focuses solely on clinical evidence. Recommendations may vary from "for research only" to "for use with standard arrangements for clinical governance, consent, and audit." Recommendations are not binding, although they are followed by providers and commissioners.

In November 2022, NICE published five new IPGs and made the following conclusions:

Medical Technologies Guidance (MTG) evaluates new, innovative medical devices and diagnostics. It looks at medical technologies that deliver treatment, like those implanted during surgical procedures, give greater independence to patients, or detect or monitor medical conditions.

In November 2022, NICE issued two new MTGs:

NICE made the following conclusions:

  • GreenLight XPS is recommended as an option to treat benign prostatic hyperplasia (BPH) in adults. Data should continue to be collected on cost-saving outcomes for GreenLight XPS compared with other treatments in people who may be considered high-risk. This includes people with larger prostates and a higher risk of bleeding. The cost modeling suggests GreenLight XPS is likely cost-saving compared with TURP and holmium laser enucleation of the prostate (HoLEP). The amount of savings depends on day case proportions, length of stay, and procedure length;
  • Optilume is recommended as an option to treat recurrent bulbar urethral strictures in adults only if comparative data is collected on patient-reported outcome measures and reintervention rates. The cost analysis shows that Optilume is cost-saving at five years compared with standard care (urethral dilatation, urethrotomy, and urethroplasty). The uncertainty about the likelihood of recurrence in the long term limits the reliability of the long-term cost savings.

One new clinical guideline, “Subarachnoid hemorrhage caused by a ruptured aneurysm: diagnosis and management”, was published in November 2022. Recommendations were made for assessment, diagnosis, and managing the culprit aneurysm, complications, and non-culprit (unruptured) aneurysms. A treatment plan for the culprit aneurysm should consider the following options: endovascular coiling, neurosurgical clipping, or no interventional procedure, with monitoring to check for clinical improvement and reassess the options for treatment.

One clinical guideline, “Fractures (complex): assessment and management”, was updated in November 2022. NICE reviewed the evidence on negative pressure wound therapy and made a new recommendation for using a temporary dressing.

See the full details for guidance here.

This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). First EU issues of both newsletters are available for download free-of-charge.

Not ready for a subscription service? Subscribe to our free-of-charge newsletter delivered every second week to get updates about key reimbursement developments in Europe (10-12 news every two weeks).